 The FDA has designated Orphan Drug Status to Sigilon Therapeutics Incs NASDAQ: SGTX SIG-007 to treat Fabry disease. It is a rare genetic disorder caused by AGAL deficiency and the accumulation of specific substrates within a patients cells, contributing to multi-organ complications. 